Method of structure-based drug design to create or improve modulators of IL-1 activity which bind to the interleukin-1 type 1 receptor
US7144988B2 · kind B2 · utility
0Cited by
0References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 14, 2003 |
| Grant date | Dec 5, 2006 |
| Priority date | — |
| Expiry date | May 21, 2024 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG16B15/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Crystals comprising a modified interleukin-1 type 1 receptor (IL-1R1) and one or more modulators of IL-1 activity are described. Methods of identifying potential inhibitors of IL-1 activity are also described. Compositions and methods for the treatment of IL-1 mediated diseases, such as rheumatoid arthritis, osteoarthritis, and other inflammatory conditions, are described.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.